Phase 1 Study of ATR-101 in Subjects With Advanced Adrenocortical Carcinoma
Status:
Completed
Trial end date:
2017-10-17
Target enrollment:
Participant gender:
Summary
This first-in-human study is designed to establish the safety and tolerability of ATR-101 in
patients with advanced adrenocortical carcinoma whose tumor has progressed on standard
therapy. Information will also be collected to determine how long ATR-101 stays in the blood,
and if any effect on tumor progression is seen. Biomarkers (blood and urine tests) will
determine if any effects on production of steroid hormones (cortisol, aldosterone, estrogen
and testosterone) are seen.